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e.	 Responsiveness,	 defined	 as	 above,	
should	be	sustained	during	at	 least	
three	months	to	confirm	continuation	
of	BH4	treatment	(this	observational	
period	can	be	prolonged	 in	 case	of	
intercurrent	illness).
5.	 A	 standard	 dosage	 of	 10	 mg/kg/day	
administered	once	daily	is	recommended	
in	children,	with	a	maximum	total	dose	of	
800	mg/day	in	adults.	In	our	experience,	
there	is	so	far	no	proven	advantage	that	
higher	doses	are	effective	to	obtain	full	
responsiveness.
6.	 PKU	 women	 during	 pregnancy	 need	 a	
strict	 control	 of	 their	 blood	 Phe	 level	
in	 order	 to	 prevent	 severe	 embryo-
foetopathy	 (maternal	 PKU);	 there	 are	
not	 enough	 data	 on	 the	 use	 of	 BH4	 in	
pregnancy	 in	 responsive	 patients	 and	
its	 use	 is	 therefore	 not	 recommended.	
However,	 in	 patients	 with	 major	 prob-
lems	 in	maintaining	blood	Phe	 levels	 in	
the	safe	range	under	dietary	control,	the	
administration	of	BH4	may	present	fewer	
risks	than	elevated	Phe	levels	and	should	
therefore	be	considered	for	treatment.		
7.	 The	SGIEM	recommends	limitation	of	BH4	
prescription	to	the	metabolic	specialists	
in	the	University	Hospitals	in	Switzerland,	
as	for	other	highly	expensive	treatments	
for	inborn	errors	of	metabolism.	
8.	 The	 SGIEM	 recommends	 that	 pharmaco-
economical	 studies	 should	 be	 performed	
to	address	the	economic	and	ethical	issues	
linked	to	the	cost/benefit	of	the	medication.
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BH4	 is	 the	 natural	 cofactor	 of	 the	 enzyme	
phenylalanine	 (Phe)	 hydroxylase,	 which	 is	
deficient	in	PKU	patients.	Since	1999,	several	
studies	have	shown	that	some	PKU	patients	
may	benefit	from	BH4	treatment1),	2),	3),	4).	There	
is	currently	no	international	consensus	about	
the	 clinical	 and	 biochemical	 criteria	 for	 as-
sessing	BH4	responsiveness	and	for	treating	
PKU	patients.	First	hand	clinical	experience	
with	BH4	treatment	has	been	gained	in	Swiss	
metabolic	 centers,	 as	 a	 limited	 number	 of	
PKU	 patients	 have	 been	 treated	 with	 BH4	
since	2003.	Due	to	the	recent	introduction	of	
Sapropterin	(Kuvan®)	on	the	Swiss	market	by	
Merk-Serono,	 BH4	 therapy	 has	 become	 far	
more	expensive	than	dietary	treatment.	In	or-
der	to	provide	a	reasonable	and	homogenous	
approach	 to	 the	 treatment	 of	 PKU	 patients	
with	 BH4	 in	 Switzerland,	 the	 Swiss	 Group	
for	Inborn	Errors	of	Metabolism	(SGIEM)	has	
reached	consensus	on	criteria	for	treatment	
and	 responsiveness	 assessment,	 based	 on	
the	current	knowledge	in	the	field,	the	experi-
ence	of	the	Swiss	centers,	and	the	published	
swiss	recommendations	for	the	treatment	of	
PKU	and	hyperphenylalaninemia.5)
The	SGIEM	recommends	the	use	of	BH4	in	
PKU	patients	under	the	following	conditions:	
1.	 BH4	oral	treatment	should	be	considered	
only	 in	 PKU	 patients	 requiring	 dietary	
treatment	(blood	Phe	level	>	400	µmol/L);	
it	 should	 not	 be	 considered	 in	 patients	
with	mild	 hyperphenylalaninemia	 (blood	
Phe	level	<	400	µmol/L	under	free	diet	in	
the	first	10	years;	blood	Phe	level	<	600	
µmol/L	under	free	diet	after	10	years).5)
2.	 BH4	 should	 be	 used	 in	 PKU	 patients	
without	 age	 restriction	 (off-label	 use	
under	 4	 years	 of	 age).	 Assessment	 of	
BH4	 responsiveness	 is	 recommended	
either	at	diagnosis	(newborn	screening)	
or	 once	 individual	 Phe	 tolerance	 has	
been	defined,	which	may	be	best		before	
weaning	(4–5	months	of	age).	
3.	 Only	 fully	 responsive	 PKU	 patients	
should	 be	 considered	 for	 treatment.	
Fully	 responsive	patients	should	 reach	
a	Phe	intake	corresponding	to	the	mini-
mum	 safe	 protein	 intake	 for	 age	 (ac-
cording	 to	 DACH	 Reference	 values)	
under	BH4.	Partially	responsive	patients	
exist,	who	increase	their	Phe	tolerance	
by	 several	 hundreds	 mg	 of	 phenylala-
nine	but	are	not	on	a	free	diet	under	BH4	
treatment.	These	patients	are,	at	pres-
ent,	not	candidates	 for	BH4	treatment	
due	to	the	limited	benefit	in	relation	with	
the	high	cost	of	the	medication.	
4.	 Assessment	 of	 BH4	 responsiveness	
should	be	done	in	the	following	way:
a.	 Therapeutic	 trial	 with	 BH4	 10	 mg/
kg/day	(1x/day)	for	4	weeks,	regard-
less	of	baseline	blood	Phe	levels.	
b.	 Blood	 Phe	 controls	 2x/week;	 daily	
dietary	 protocol	 for	 Phe	 intake	 cal-
culation.
c.	 Progressive	 increase	 of	 Phe	 intake	
up	 to	 a	 level	 corresponding	 to	 the	
minimum	safe	protein	intake	for	age	
by	 the	 end	 of	 the	 4	week	 trial.	 The	
additional	Phe	intake	should	be	given	
as	milk	powder,	to	mix	with	the	usual	
amino-acid	mixture.	No	other	protein-
rich	food	should	be	introduced	before	
establishing	patient’s	responsiveness.	
d.	 Responsive	 patients	 should	 keep	
blood	 Phe	 levels	 below	 the	 recom-
mended	 thresholds	 for	 age	 while	
receiving	a	diet	corresponding	to	the	
minimum	safe	protein	intake	for	age	
(blood	 Phe	 <	 300	 µmol/L	 between	
0	and	2	years;	<	400	µmol/L	under	
10	years;	600	µmol/L	above	the	age	
of	10	years).5)	If	blood	Phe	levels	in-
crease	above	the	recommended	safe	
thresholds	after	the	first	steps	of	in-
creased	Phe	intake,	in	the	absence	of	
illness	or	other	catabolic	factors,	the	
patient	is	considered	non-responsive	
and	the	trial	can	be	stopped.
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